Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL724776 | 1.00 | KDM4E (0.52) | KDM4EBLMNPSR1CYP2D6CYP2C19 | |
| Sulfuric Acid SCHEMBL9724618 | 0.85 | KDM4E (0.50) | KDM4EBLMNPSR1CYP2D6CYP2C19 | |
| Sulfuric Acid SCHEMBL10751111 | 0.85 | KDM4E (0.50) | KDM4EBLMNPSR1CYP2D6CYP2C19 | |
| SCHEMBL33703 | 0.83 | — | — | |
| SCHEMBL349631 | 0.83 | — | — | |
| Urea SCHEMBL28979500 | 0.80 | LMNA (0.43) | KDM4EBLMNPSR1CYP2D6CYP2C19 | |
| Bromide SCHEMBL27402570 | 0.79 | — | — | |
| Methane SCHEMBL28838054 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL29018408 | 0.79 | — | — | |
| Guanidine SCHEMBL27115146 | 0.79 | LMNA (0.45) | LMNADPP4ADRA1AHTTHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3971182-B1 | 2-SUBSTITUTED AMINO-NAPHTH[1,2-D]IMIDAZOL-5-ONE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | PTC THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12521367-B2 | Related formulations and methods related to eye irritation | LEBRUN LABS LLC (US) | 2026-01-13 | — | — | US | disclosed |
| US-12281083-B2 | 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof | PTC THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-119504571-A | Right-embedded alcohol or fenchyl alcohol ester derivatives of 2-hydroxy nicotinic acid and pharmaceutical application thereof | 苏州缘聚医药科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12115147-B2 | Formulations and methods related to eye irritation | LEBRUN LABS LLC (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240082214-A1 | RELATED FORMULATIONS AND METHODS RELATED TO EYE IRRITATION | LEBRUN LABS LLC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20230390239-A1 | FORMULATIONS AND METHODS RELATED TO EYE IRRITATION AND RELATED | LEBRUN LABS LLC (US) | 2023-12-07 | — | — | US | disclosed |
| US-20230247997-A1 | NEMATICIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF THEIR MAKING AND USE | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2023-08-10 | — | — | US | disclosed |
| EP-4182305-A1 | NEMATICIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF THEIR MAKING AND USE | Iowa State University Research Foundation, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20230116786-A1 | 2-SUBSTITUTED AMINO-NAPHTH (1,2-D) IMIDAZOL-5-ONE COMPOUNDS OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | PTC THERAPEUTICS INC (US) | 2023-04-13 | — | — | US | disclosed |
| US-20160264536-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3061754-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-08-31 | — | — | EP | disclosed |
| EP-1453858-B1 | PROCESS FOR RENATURATION OF RECOMBINANT, DISULFIDE CONTAINING PROTEINS AT HIGH PROTEIN CONCENTRATIONS IN THE PRESENCE OF AMINES | BAYER SCHERING PHARMA AG (DE) | 2011-01-12 | — | — | EP | disclosed |
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1483257-A1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2003076427-A1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2003-09-18 | — | — | WO | disclosed |
| EP-0693073-B1 | BICYCLIC ANSAMYCINS AND THEIR USE AS ANTITUMOR AGENTS | PFIZER (US) | 1998-06-03 | — | — | EP | disclosed |
| US-5387584-A | Bicyclic ansamycins | PFIZER INC. (US) | 1995-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | ADRA1A 13/4885KDM4E 2413/4885BLM 1081/4885 |
| US-12281083-B2 | 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof | GLS2, GOT2, SMN1; SMN2 | ADRA1A 421/4885KDM4E 4603/4885BLM 2523/4885 |
| US-20230116786-A1 | 2-SUBSTITUTED AMINO-NAPHTH (1,2-D) IMIDAZOL-5-ONE COMPOUNDS OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | GLS2, GOT2, SMN1; SMN2 | ADRA1A 421/4885KDM4E 4603/4885BLM 2523/4885 |
| US-20160264536-A1 | HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | ADRA1A 474/4885KDM4E 2320/4885BLM 3303/4885 |
| US-20230247997-A1 | NEMATICIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF THEIR MAKING AND USE | ACHE, NISCH, CASP7 | ADRA1A 3491/4885KDM4E 2365/4885BLM 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.